Holen Sie sich die Stockscreener-App
21.90
0.97%
0.20
Schlusskurs vom Vortag:
$21.70
Offen:
$21.71
24-Stunden-Volumen:
68,936
Relative Volume:
0.05
Marktkapitalisierung:
$3.21B
Einnahmen:
$460.48M
Nettoeinkommen (Verlust:
$142.80M
KGV:
18.56
EPS:
1.18
Netto-Cashflow:
$221.79M
1W Leistung:
-0.73%
1M Leistung:
-12.22%
6M Leistung:
+4.98%
1J Leistung:
+38.93%
1-Tages-Spanne:
$21.67
$21.97
1-Wochen-Bereich:
$21.40
$22.11
52-Wochen-Spanne:
$14.97
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Firmenname
Catalyst Pharmaceuticals Inc
Sektor
Branche
Telefon
(305) 529-2522
Adresse
355 ALHAMBRA CIRCLE, CORAL GABLES
Vergleichen Sie CPRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
21.92 | 3.21B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.98 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
524.33 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.12 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
556.95 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.72 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-03-14 | Eingeleitet | Citigroup | Buy |
| 2024-03-07 | Eingeleitet | BofA Securities | Buy |
| 2023-12-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-24 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-07 | Fortgesetzt | Piper Jaffray | Overweight |
| 2016-10-05 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | Bestätigt | ROTH Capital | Buy |
| 2014-09-16 | Bestätigt | ROTH Capital | Buy |
| 2014-09-15 | Bestätigt | H.C. Wainwright | Buy |
| 2013-10-21 | Bestätigt | Aegis Capital | Buy |
| 2013-09-24 | Eingeleitet | Maxim Group | Buy |
| 2013-09-06 | Bestätigt | Aegis Capital | Buy |
| 2013-04-18 | Eingeleitet | Aegis Capital | Buy |
| 2012-08-27 | Hochstufung | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | Hochstufung | Merriman | Sell → Neutral |
| 2009-05-29 | Herabstufung | Hapoalim | Neutral → Underperform |
| 2009-05-29 | Herabstufung | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | Eingeleitet | Merriman Curhan Ford | Buy |
| 2007-11-28 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | Eingeleitet | Stifel Nicolaus | Buy |
| 2007-01-05 | Eingeleitet | First Albany | Buy |
Alle ansehen
Catalyst Pharmaceuticals Inc Aktie (CPRX) Neueste Nachrichten
Catalyst Pharmaceuticals (NasdaqCM:CPRX) Reports Strong Q1 2025 Earnings Growth - Yahoo Finance
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock - Yahoo Finance
Stanley Laman Group Ltd. Acquires New Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
GAMMA Investing LLC Has $1.64 Million Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) Trading Down 5.2% Following Insider Selling - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Insider Sells $42,272.00 in Stock - MarketBeat
Trading (CPRX) With Integrated Risk Controls - news.stocktradersdaily.com
Preethi Sundaram Implements A Sell Strategy: Offloads $103K In Catalyst Pharmaceuticals Stock - Nasdaq
Wesbanco Bank Inc. Invests $461,000 in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Insider Sell: Preethi Sundaram Sells Shares of Catalyst Pharmaceuticals Inc (CPRX) - GuruFocus
Preethi Sundaram Sells 2,324 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock - MarketBeat
117,374 Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Bought by Bridge City Capital LLC - MarketBeat
Director Of Catalyst Pharmaceuticals Sold $5.22M In Stock - Nasdaq
Insider Sell: Patrick Mcenany Sells 200,000 Shares of Catalyst P - GuruFocus
Catalyst Pharmaceuticals, Inc. (CPRX) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Catalyst Pharmaceuticals stock soars to all-time high of $26.49 By Investing.com - Investing.com South Africa
Catalyst Pharmaceuticals stock soars to all-time high of $26.49 - Investing.com Australia
Catalyst Pharmaceuticals (NASDAQ:CPRX) Upgraded by Cantor Fitzgerald to "Strong-Buy" Rating - MarketBeat
Catalyst (CPRX) Up 11.4% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock - Yahoo Finance
If You Invested $1000 in Catalyst Pharmaceutical a Decade Ago, This is How Much It'd Be Worth Now - MSN
Catalyst Pharmaceuticals (CPRX) CEO Acquires 70,000 Shares | CPR - GuruFocus
What Makes Catalyst Pharmaceutical (CPRX) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Insider Sell: Richard Daly Sells 70,000 Shares of Catalyst Pharm - GuruFocus
Catalyst Pharmaceuticals (CPRX) CEO Acquires 70,000 Shares | CPRX Stock News - GuruFocus
Catalyst Pharmaceuticals (NasdaqCM:CPRX) Appoints Dr. William Andrews As New Chief Medical Officer - Yahoo Finance
Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term - Yahoo Finance
Catalyst Pharmaceuticals names new Chief Medical Officer By Investing.com - Investing.com South Africa
Catalyst Pharma Appoints New Chief Medical Officer - TipRanks
Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer - GlobeNewswire
Catalyst Pharmaceuticals names new Chief Medical Officer - Investing.com
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term - Yahoo Finance
Catalyst Pharmaceuticals (CPRX) Names New Chief Medical Officer | CPRX Stock News - GuruFocus
Catalyst Pharmaceuticals Announces Appointment of William T. And - GuruFocus
Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer | CPRX Stock News - GuruFocus
Catalyst Pharmaceuticals Taps Harvard-Yale Veteran with 18 Years Rare Disease Expertise as New CMO - Stock Titan
What is Zacks Research’s Forecast for CPRX FY2025 Earnings? - Defense World
(CPRX) Trading Report - news.stocktradersdaily.com
Catalyst: Solid Business Model Propels Growth For This Buy And Build Pharma (NASDAQ:CPRX) - Seeking Alpha
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Zacks Research Brokers Raise Earnings Estimates for CPRX - Defense World
Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Earnings Are Not Doing Enough For Some Investors - simplywall.st
ProShare Advisors LLC Boosts Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
D. E. Shaw & Co. Inc. Buys Shares of 18,173 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Position Decreased by Jane Street Group LLC - Defense World
Cetera Investment Advisers Grows Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Ameriprise Financial Inc. Grows Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Transcript : Catalyst Pharmaceuticals, Inc.Shareholder/Analyst Call - marketscreener.com
Catalyst Pharmaceuticals at Bank of America 2025: Strategic Expansion and Growth - Investing.com Canada
Transcript : Catalyst Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 08 - marketscreener.com
The Strong Earnings Posted By Catalyst Pharmaceuticals (NASDAQ:CPRX) Are A Good Indication Of The Strength Of The Business - Yahoo Finance
Finanzdaten der Catalyst Pharmaceuticals Inc-Aktie (CPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Catalyst Pharmaceuticals Inc-Aktie (CPRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sundaram Preethi | Chief Strategy Officer |
Jun 11 '25 |
Sale |
26.42 |
1,600 |
42,272 |
41,081 |
0.58%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):